Galcanezumab: First Global Approval
Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults. In the same month, the EMA issued a positive opinion for galcanezumab for the prophylaxis of migraine in adults who have at least 4 migraine days per month. Galcanezumab is also undergoing phase III evaluation for the preventive treatment of cluster headache in North America and Europe. This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 4.Eli Lilly and Company. Lilly’s Emgality™ (galcanezumab-gnlm) receives U.S. FDA approval for the preventive treatment of migraine in adults [media release]. 5 Oct 2018. http://investor.lilly.com/.
- 5.Eli Lilly and Company. EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use: US prescribing information. 2018. http://pi.lilly.com/. Accessed 11 Oct 2018.
- 6.European Medicines Agency. Summary of opinion: Emgality (galcanezumab). 2018. http://www.ema.europa.eu/. Accessed 11 Oct 2018.
- 7.Eli Lilly and Company. Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study [media release]. 17 June 2015. http://www.lilly.com/.
- 8.Eli Lilly and Company. Lilly announces acquisition of CGRP antibody for migraine prevention from Arteaus Therapeutics [media release]. 13 Jan 2014. http://www.lilly.com/.
- 9.Atlas Venture. Arteaus Therapeutics, LLC raises $18 M to prevent migraines [media release]. 19 Oct 2011. http://www.atlasventure.com/.
- 11.Kielbasa W, O’Brien L, Moser B, et al. Assessment of pharmacokinetics, target engagement and immunogenicity in patients with migraine administered galcanezumab, an anti-CGRP antibody [abstract no. IOR09]. Headache. 2018;58 (Suppl 2):77–8.Google Scholar
- 14.Aurora S, Detke H, Millen B. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: post-hoc analyses of two phase 3 studies [abstract no. IOR05]. Headache. 2018;58 (Suppl. 2):75.Google Scholar
- 15.Detke HC, Wang S, Skljarevski V, et al. A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study [abstract no. PS89LB]. Headache. 2017;57(8):1336–7.Google Scholar
- 16.Eli Lilly and Company. Summary of the efficacy and safety of galcanezumab in phase 3, randomized, double-blind, placebo-controlled studies. 2017. http://www.headache.mobi/. Accessed 11 Oct 2018.
- 17.Eli Lilly and Company. IHC 2017: Lilly’s galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine [media release]. 8 Sep 2017. http://www.lilly.com/.
- 19.Eli Lilly and Company. Galcanezumab (LY2951742) CGRP monoclonal antibody for the prevention of migraine: phase 2, randomized, double-blind, placebo-controlled studies, ART01 and CGAB. 2017. http://www.headache.mobi/. Accessed 11 Oct 2018.
- 21.Martinez JM, Goadsby PJ, Dodick DW, et al. Study CGAL: a placebo-controlled study of galcanezumab in patients with episodic cluster headache: results from the 8-week double-blind treatment phase [abstract no. 33]. Postgrad Med. 2018;130(Suppl. 1):24–5.Google Scholar
- 22.Eli Lilly and Company. Lilly’s galcanezumab meets primary endpoint in phase 3 study evaluating galcanezumab for the prevention of episodic cluster headache [media release]. 15 May 2018. http://www.lilly.com/.